Measuring translational research impact requires reaching beyond current metrics

Georg N Duda; David W Grainger; Robert E Guldberg; Gady Goldsobel; Glenn D Prestwich; Brenna Rauw; Hans-Dieter Volk

doi:10.1126/scitranslmed.abp8258

Measuring translational research impact requires reaching beyond current metrics

Sci Transl Med. 2023 Aug 2;15(707):eabp8258. doi: 10.1126/scitranslmed.abp8258. Epub 2023 Aug 2.

Authors

Georg N Duda^{1

2}, David W Grainger^{3

4}, Robert E Guldberg⁵, Gady Goldsobel¹, Glenn D Prestwich⁶, Brenna Rauw⁷, Hans-Dieter Volk^{1

8}

Affiliations

¹ Berlin Institute of Health Center for Regenerative Therapies, BIH at Charité - Universitätsmedizin Berlin, Berlin, Germany.
² Julius Wolff Institute, BIH at Charité - Universitätsmedizin Berlin, Berlin, Germany.
³ Department of Molecular Pharmaceutics, Health Sciences, University of Utah, Salt Lake City, UT, USA.
⁴ Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.
⁵ Phil and Penny Knight Campus for Accelerating Scientific Impact, University of Oregon, Eugene, OR, USA.
⁶ Clear Solutions Biomedical LLC, Poulsbo, WA, USA.
⁷ Modern Meadow, Inc., Nutley, NJ, USA.
⁸ Institute Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

PMID: 37531418
DOI: 10.1126/scitranslmed.abp8258

Abstract

Translational impact assessment is key to selecting those biomedical research discoveries most likely to be converted into viable new products to improve human health. However, metrics for translational success are variable, are not limited to commercial success, and may not be relevant to every case or institution. Societal impact is a top translational priority in a globalized society.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Benchmarking
Biomedical Research*
Humans
Translational Research, Biomedical*